Priority Lists
Protocol Posting of
Activations
Evaluation of CHOP Plus Involved Field Radiotherapy followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE and non-bulky Stages II and IIE, CD20 Positive, High-risk Localized, Aggressive Histologies of Non-Hodgkin's Lymphoma, Phase II
| Study Coordinator(s) | Thomas P. Miller, M.D., Louis S. Constine, M.D., B. Dino Stea, M.D.,Ph.D., Catherine Spier, M.D. |
| Participants | Limited: Institutions Listed on the Title Page |
Closures
Repository for Paraffin Embedded Tissues from Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
| Study Coordinator(s) | Wolfram E. Samlowski, M.D., Heinz- Josef Lenz, M.D., Joseph A. Holden, M.D., Kurt H. Albertine, Ph.D. |
| Participants | Members, Medical Oncologists, Pathologists, NCORP |
| Closure Date | 2004-02-15 |
Amendments, Revisions, Memoranda
Memorandum
A Phase II Study of 506U78 in Patients with Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
| Study Coordinator(s) | Steven E. Coutre, M.D., Alison T. Stopeck, M.D. |
| Participants | Pathologists, NCORP, Members |
Amendment #1
A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) And Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) For Patients with AL Amyloidosis or High Risk (greater than or equal to Age 70 or Poor Renal Function)Patients With Multiple Myeloma(A BMT Study)
| Action Codes | AC, FBR |
| Study Coordinator(s) | Vaishali Sanchorawala, M.D., David C. Seldin, M.D.,Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, Limited Institutions: BMT Members |
Revision #4
Randomized Phase III Trial of Cisplatin and Irinotecan versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer
| Study Coordinator(s) | Ronald B. Natale, M.D., David R. Gandara, M.D., Primo N. Lara, Jr., M.D., Heinz- Josef Lenz, M.D. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists, Pathologists, CTSU |
Revision #1
A Phase II Study of Chimerism-Mediated Immunotherapy (CMI) Using Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation in Older Patients With Acute Myeloid Leukemia (AML) in First Complete Remission (A BMT Study)
| Study Coordinator(s) | Peter A. McSweeney, M.D., Thomas R. Chauncey, M.D.,Ph.D., Scott I. Bearman, M.D., Anwar N. Mohamed, M.D., Cheryl L. Willman, M.D. |
| Participants | Limited Institutions: Allogeneic BMT Members |
Revision #2
Docetaxel (NSC-628503), Cisplatin (NSC-119875), and 5-Fluorouracil (NSC-19893) Induction Chemotherapy Followed by Accerlerated Fractionation/Concomitant Boost Radiation and Concurrent Single Agent Cisplatin (NSC-119875), in Patients with Advanced Squamous Cell Head and Neck Cancer
| Study Coordinator(s) | David J. Adelstein, M.D., Ehab Hanna, M.D., P.G. Shankar Giri, M.D., S.G. Urba, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists |
Revision #2
A Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors)
| Study Coordinator(s) | Michael J. Kraut, M.D., Katherine M. W. Pisters, M.D., Joshua Sonett, M.D., Charles R. Thomas Jr., M.D., Valerie W. Rusch, M.D. |
| Participants | Members, NCORP, Medical Oncologists, ECOG, NCIC-CTG, ACOSOG, NCCTG, CALGB |
Revision #3
Myeloma Specimen Repository Protocol, Ancillary
| Action Codes | ER |
| Study Coordinator(s) | Lisa M. Rimsza, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
Amendment #1
A Phase II Trial of STI-571/Imatinib (Gleevec®) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)
| Study Coordinator(s) | Wolfram E. Samlowski, M.D., Ralph J. Tuthill, M.D., Michael C. Heinrich, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, ECOG |
Revision #4
Long Term Follow-Up Protocol: An Administrative Tool.
| Participants | Members, NCORP, UCOP |
Revision #12
Cytogenetic, Molecular and Cellular Biology Studies in Metastatic Melanoma Patients, Ancillary
| Study Coordinator(s) | Jeffrey A. Sosman, M.D., Vernon K. Sondak, M.D., Ralph J. Tuthill, M.D., Cecilia M. Fenoglio-Preiser, M.D., Marilyn L. Slovak, Ph.D., Robert P. Whitehead, M.D., Diane L. Persons, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, ECOG |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required